[go: up one dir, main page]

RU2015116116A - APPLICATION OF LIPOSOMAL EMULSION WITH "FLAMENA" DIHYDROQUERCETIN FOR THE TREATMENT OF CHRONIC ENDOMETRITIS WITH AUTOIMMUNE DISORDERS IN INFERTILITY - Google Patents

APPLICATION OF LIPOSOMAL EMULSION WITH "FLAMENA" DIHYDROQUERCETIN FOR THE TREATMENT OF CHRONIC ENDOMETRITIS WITH AUTOIMMUNE DISORDERS IN INFERTILITY Download PDF

Info

Publication number
RU2015116116A
RU2015116116A RU2015116116A RU2015116116A RU2015116116A RU 2015116116 A RU2015116116 A RU 2015116116A RU 2015116116 A RU2015116116 A RU 2015116116A RU 2015116116 A RU2015116116 A RU 2015116116A RU 2015116116 A RU2015116116 A RU 2015116116A
Authority
RU
Russia
Prior art keywords
dihydroquercetin
stage
therapy
emulsion
treatment
Prior art date
Application number
RU2015116116A
Other languages
Russian (ru)
Other versions
RU2622024C2 (en
Inventor
Нина Павловна Лапочкина
Элисса Алексеевна Овчарук
Original Assignee
Общество с ограниченной ответственностью "Флавимакс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Флавимакс" filed Critical Общество с ограниченной ответственностью "Флавимакс"
Priority to RU2015116116A priority Critical patent/RU2622024C2/en
Publication of RU2015116116A publication Critical patent/RU2015116116A/en
Application granted granted Critical
Publication of RU2622024C2 publication Critical patent/RU2622024C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1. Способ лечения нарушений репродуктивной функции, связанных с хроническим эндометритом с аутоиммунными нарушениями, представляющий собой комплексную терапию, включающую 4 этапа лечения, каждый из которых проводится последовательно в разные следующие друг за другом менструальные циклы и представляет собой:1. A method of treating reproductive disorders associated with chronic endometritis with autoimmune disorders, which is a complex therapy that includes 4 stages of treatment, each of which is carried out sequentially in different consecutive menstrual cycles and is: 1 этап - энзимотерапия, применение ангиопротекторов;Stage 1 - enzyme therapy, the use of angioprotectors; 2 этап - метаболическая терапия, физиолечение, энзимотерапия, применение ангиопротекторов, а также введение в полость матки липосомальной эмульсии с дигидрокверцетином;Stage 2 - metabolic therapy, physiotherapy, enzyme therapy, the use of angioprotectors, as well as the introduction of a liposome emulsion with dihydroquercetin into the uterine cavity; 3 этап - гормонотерапия, физиотерапия, а также введение в полость матки липосомальной эмульсии с дигидрокверцитином;Stage 3 - hormone therapy, physiotherapy, as well as the introduction of a liposome emulsion with dihydroquercin in the uterine cavity; 4 этап - прегравидарная подготовка, гормонотерапия, а также введение в полость матки липосомальной эмульсии с дигидрокверцетином;Stage 4 - pregravid preparation, hormone therapy, as well as the introduction of a liposome emulsion with dihydroquercetin into the uterine cavity; где липосомальная эмульсия с дигидрокверцетином имеет следующий состав, мг/мл:where the liposomal emulsion with dihydroquercetin has the following composition, mg / ml: лецитинlecithin 30 thirty дигидрокверцетинdihydroquercetin 3,8±0,2  3.8 ± 0.2 глицинglycine 35±5  35 ± 5 вода очищеннаяpurified water остальное rest
и применяется на 2-4 этапе комплексного лечения согласно следующему режиму введения, и в следующих терапевтических дозировках: с 5-6 дня менструального цикла после обработки влагалища и цервикального канала асептическим раствором в полость матки вводится липосомальная эмульсия с дигидрокверцетином, предварительно подогретая до 37°С в количестве не более 2,0 мл в течение 10 дней.and is applied at the 2–4 stage of complex treatment according to the following regimen of administration, and in the following therapeutic dosages: from the 5–6 day of the menstrual cycle after the vagina and cervical canal are treated with aseptic solution, a liposomal emulsion with dihydroquercetin is introduced into the uterine cavity, preheated to 37 ° C in an amount of not more than 2.0 ml for 10 days. 2. Способ по п. 1, в котором хронический эндометрит с аутоиммунными нарушениями представляет собой аутоиммунный хронический эндометрит или хронический эндометрит с аутоиммунным компонентом.2. The method of claim 1, wherein the chronic endometritis with autoimmune disorders is an autoimmune chronic endometritis or chronic endometritis with an autoimmune component. 3. Способ по п. 1, характеризующийся тем, что на первом этапе лечения дополнительно осуществляют антибактериальную, противовирусную и/или противогрибковую терапию.3. The method according to p. 1, characterized in that at the first stage of treatment, antibacterial, antiviral and / or antifungal therapy is additionally carried out.
RU2015116116A 2015-12-01 2015-12-01 Application of liposomal dihydroquercetin emulsion "flamena" for treatment of chronic endometritis with autoimmune disorders in case of infertility RU2622024C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2015116116A RU2622024C2 (en) 2015-12-01 2015-12-01 Application of liposomal dihydroquercetin emulsion "flamena" for treatment of chronic endometritis with autoimmune disorders in case of infertility

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015116116A RU2622024C2 (en) 2015-12-01 2015-12-01 Application of liposomal dihydroquercetin emulsion "flamena" for treatment of chronic endometritis with autoimmune disorders in case of infertility

Publications (2)

Publication Number Publication Date
RU2015116116A true RU2015116116A (en) 2017-06-02
RU2622024C2 RU2622024C2 (en) 2017-06-08

Family

ID=59031504

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015116116A RU2622024C2 (en) 2015-12-01 2015-12-01 Application of liposomal dihydroquercetin emulsion "flamena" for treatment of chronic endometritis with autoimmune disorders in case of infertility

Country Status (1)

Country Link
RU (1) RU2622024C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2715144C2 (en) * 2018-07-23 2020-02-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method of treating partial cicatricial inconsistency after caesarean section
RU2766681C1 (en) * 2021-03-24 2022-03-15 Антон Владимирович Евтеев Use of phospholipid emulsion containing effective amount of dihydroquercetin for treating ischemia-reperfusion syndrome in patients with ischemic organ and extremity injuries
RU2757360C1 (en) * 2021-03-24 2021-10-14 Общество с ограниченной ответственностью "Научная Компания "Фламена" Use of a phospholipid emulsion containing an effective amount of dihydroquercetin, lecithin and glycine for the treatment of inflammatory diseases of the respiratory system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA23364A (en) * 1995-01-03 1998-08-31 Тернопільський Медичний Інститут Ім. Акад. І.Я.Горбачевського Method for treatment of acute endometritis
RU2158598C2 (en) * 1998-04-21 2000-11-10 Иркутский институт химии СО РАН Method of preparing dihydroquercetin
RU2342173C1 (en) * 2007-03-26 2008-12-27 Общество с ограниченной ответственностью "МАДЕЗ" (ООО "МАДЕЗ") Treatment method for chronic endometritis
RU2369383C2 (en) * 2007-10-30 2009-10-10 Общество с ограниченной ответственностью "Научная Компания "Фламена" Phospholipid suspension containing dihydroquercetin and method for producing
RU2499594C1 (en) * 2012-04-16 2013-11-27 Алексей Аркадьевич Чураков Method of treating chronic endometritis

Also Published As

Publication number Publication date
RU2622024C2 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
MX2021002321A (en) Novel methods.
RU2017134443A (en) METHOD OF TREATMENT WITH USE OF TRADIPTANT
RU2014150942A (en) TREATMENT OF SIDE EFFECTS IN THE FORM OF MOTOR AND MOTOR DISORDERS RELATED TO THE TREATMENT OF PARKINSON'S DISEASE
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
FI3493812T3 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
BR112018070017A2 (en) Pediatric Cancer Treatment Methods
EA201591701A1 (en) COMBINATION OF ANTI-VIRAL DIRECT ACTION AND RIBAVIRIN FOR THE TREATMENT OF PATIENTS WITH HCV
MX2022007911A (en) Method of treating virus infection using a tlr7 agonist.
RU2015116116A (en) APPLICATION OF LIPOSOMAL EMULSION WITH "FLAMENA" DIHYDROQUERCETIN FOR THE TREATMENT OF CHRONIC ENDOMETRITIS WITH AUTOIMMUNE DISORDERS IN INFERTILITY
JP2017533972A5 (en)
BR112015009504A2 (en) rock inhibitors
EA201990602A3 (en) COMBINATIONS OF PALMITOYLETHANOLAMIDE FOR THE TREATMENT OF CHRONIC PAIN
HRP20192189T1 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX2018000240A (en) Methods for treating hcv.
JOP20190019A1 (en) Pharmaceutical Formula for Treatment of Growth Hormone Deficiency Contains Human Growth Hormone (hGH) Fusion Protein
RU2416394C1 (en) Pharmaceutical composition in form of spray for wound surface treatment
RU2019126627A (en) DOSAGE DOSAGE FOR THE COMBINATION OF CERITINIB AND ANTIBODY MOLECULE TO PD-1
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
EA202192928A1 (en) THERAPEUTIC MEDICINE FOR THE TREATMENT OF DYSKINESIA
RU2013149635A (en) SOLIFENACIN COMPOUNDS AND SALIVARY STIMULANTS FOR THE TREATMENT OF URINE BUBBLE HYPERACTIVITY
AR101227A1 (en) COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN
RU2017135273A (en) Pyrrolidone-Carboxylic Acid (PCA) for Ophthalmic Use
WO2020139163A3 (en) Combination of antiviral agents
MX2020009204A (en) A pharmaceutical solid oral dosage form of solifenacin.
CA3154122C (en) Lag time reduction/ice spray

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20191202

NF4A Reinstatement of patent

Effective date: 20211020